Colorado Rocky Mountain Health Plans Skin Substitutes Coverage

Coverage Criteria for Skin and Soft Tissue Substitutes

EPIFIX or GRAFIX (noninjectable)

Covered when ALL of the following are met:

EPIFIX/GRAFIX for diabetic foot ulcer: Adequate circulation to the affected extremity as indicated by one or more of the following: palpable pedal pulses or pulses confirmed with Doppler OR Ankle-Brachial Index between 0.7 and 1.2; Glycated hemoglobin (HbA1c) < 12% within the last 90 days; Ulcer has failed to demonstrate adequate healing after at least 4 weeks of standard wound care that includes maintaining a moist wound environment, debridement of necrotic tissue if present, and offloading; No known contraindications (examples include active Charcot deformity or major structural foot abnormalities, chronic infection at the ulcer site, known or suspected malignancy of the ulcer, or ulcer that extends to tendon/muscle/capsule/bone).

EPIFIX or GRAFIX is proven and medically necessary for DFU when all criteria are met.

TransCyte

Covered when ALL of the following are met:

TransCyte for surgical burn wounds: Surgically excised full-thickness thermal burn wounds or deep partial-thickness thermal burn wounds being treated prior to autograft placement; use consistent with standard surgical burn care protocols.

TransCyte is proven and medically necessary for these burn indications.

Other Skin and Soft Tissue Substitutes — Not Medically Necessary

Not medically necessary for any indication due to insufficient evidence:

Other listed products — Not medically necessary: The policy lists numerous named skin and soft tissue substitute products (see product lists) that are considered unproven and not medically necessary for any indication because published studies are lacking or insufficient to determine a beneficial effect on health outcomes.

Refer to the product lists in the policy for the full enumeration of individual products.

Adjunctive use of skin substitutes for chronic wounds

Covered when ALL of the following are met:

Appropriate wound types and baseline care: Chronic wounds (e.g., diabetic foot ulcers, venous leg ulcers, pressure ulcers) or other appropriate soft tissue indications after initial evaluation; standard of care measures performed including debridement, moisture balance, infection control, correction of ischemia, and compression/offloading as applicable.

Standard of care components are described in the policy background.

Conservative treatment trial: At least 4 weeks of standard treatment without ≥50% wound size reduction prior to consideration of adjunctive skin substitute therapy.4 weeks; <50% reduction

Failure to achieve ≥50% reduction suggests escalation per policy.

Product selection and coding: Use of a product-specific HCPCS (Q/4*** or A) code with prior authorization per payer requirements and documentation linking the product, billed units, and primary procedure when applicable.

Use for burns and acute soft tissue indications

Covered when:

Burns and acute soft tissue indications: Dermal substitutes may be used for acute partial- or full-thickness burns and for partial-thickness hypertrophic scars and contractures when autograft is not appropriate or as an adjunct to standard surgical/burn care.

Standard surgical and burn care still apply.

Coverage stance by product

Products listed below are evaluated individually; coverage stance is based on available evidence for each product.

Products lacking sufficient evidence: A large number of branded amniotic/placental/dermal/fish-skin and other skin substitute products (examples listed in the policy) have few or no published studies; for these products it is not possible to determine a beneficial effect on health outcomes and coverage is not supported by current evidence.

See policy product listings for specific product names and details.

Affinity—limited RCT evidence: Affinity has a single multicenter RCT with limitations showing improved closure vs standard care in DFUs, but further trials are needed before broad conclusions; treat as limited evidence when considering coverage.

Evidence is promising but insufficient for general coverage expansion.

Insufficient Evidence / Unproven

Products lacking sufficient evidence — unable to determine clinical benefit:

Insufficient evidence group: For the listed branded amniotic/placental membrane products and many other named substitutes, published studies are lacking or few; therefore it is not possible to determine whether these products have a beneficial effect on health outcomes and they are considered unproven/unestablished for coverage.

Products include (but are not limited to) American Amnion variants, AmnioCore variants, Amnio Burgeon variants, AmnioTX, Amnio Quad-Core, Amnio Tri-Core, AmnioAMP-MP, Amnio Wound, AmnioWrap2, AmnioArmor.

AmnioBand (dHACA) — Supported by RCTs with limitations

Products with supportive randomized evidence in specific wound types:

AmnioBand (dHACA) clinical evidence: Randomized controlled trials of dehydrated human amnion/chorion allograft (AmnioBand/dHACA) plus standard of care versus standard care alone demonstrated higher healing rates and faster time to heal in diabetic foot ulcers and venous leg ulcers at short-term endpoints (up to 12 weeks), although trials had limitations (lack of blinding, moderate sizes, manufacturer involvement).

RCTs and meta-analyses summarized in policy support efficacy in trial populations.

Coverage when trial-aligned criteria are met

Covered when ALL of the following are met (based on populations and protocols used in cited trials):

Trial-consistent eligibility: Documentation of prior adequate trial of standard of care (SOC) with failure to heal as defined in trials (e.g., SOC run-in with insufficient percent area reduction); prior SOC attempts must be recorded.

RCTs employed SOC run-in periods prior to randomization.

Wound characteristics consistent with trials: Wounds similar to study inclusion criteria (e.g., noninfected diabetic foot ulcers or venous leg ulcers; Wagner grade 1 or superficial 2 in some DFU trials; wound area often between 1 and 25 cm2 depending on the study), with no signs of active infection or osteomyelitis.e.g., 1–25 cm2 as reported in some trials

Trial eligibility specifics should be mirrored in documentation.

Adequate perfusion and absence of infection: Adequate tissue perfusion documented (examples used in trials include ABI > 0.7, TcPO2 ≥ 30 mm Hg, or triphasic/biphasic Doppler waveforms) and absence of active wound infection; these criteria must be met for trial-like coverage consideration.

Insufficient evidence — not established as beneficial

Stance for listed individual products:

Insufficient evidence — product-specific: For each listed product (examples include AMNIOMATRIX/BioDMatrix, AmnioMatrixF3X/F4X, Amnio-Maxx, AmnioPlast variants, Artacent family, Architect, Ascent, and many others), there are few or insufficient published studies; therefore clinical benefit cannot be determined and coverage is not established based on current evidence.

Coverage decisions for these products require strong supportive evidence or may be denied.

Artacent — small observational study

Limited positive observational evidence:

Artacent observational data: A small observational analysis of Artacent reported healing in a per-protocol cohort of previously nonresponding DFUs (65% complete closure at 12 weeks in 26 patients), but sample size was small and the larger trial was discontinued; evidence is insufficient to support broad coverage changes.

May inform future reviews but not sufficient for general coverage.

Coverage conditional on documentation and evidence

Covered when ALL of the following are met (as implied by evidence requirement and registry context):

Documented failure of standard care: Documented failure or contraindication to standard wound care (e.g., debridement, infection control, offloading or compression) prior to use of the product; provide dates and objective measures of response to SOC.

Registry and limited-study contexts emphasize usual-care variability and the need to document prior therapies.

Product-specific supporting evidence: Submission includes product-specific clinical evidence, registry data, or rationale demonstrating potential benefit for the individual patient; absent published studies, noncoverage or denial is possible.

Many products lack published studies; coverage evaluated case-by-case with documentation.

General coverage posture: insufficient evidence / investigational

Summary coverage posture based on evidence in this section:

General coverage posture: Amniotic/placental/umbilical, dermal, porcine ECM, and many other reviewed products generally lack sufficient high-quality published studies to determine clinical benefit; use of these products should be considered investigational or unproven for wound treatment unless high-quality comparative evidence is provided.

Derived from repeated statements of insufficient evidence across product sections.

CorMatrix — cardiovascular applications

Products with mixed or concerning clinical outcomes:

CorMatrix cardiovascular outcomes: Clinical studies of CorMatrix in cardiovascular applications report heterogeneous results with variable inflammation, minimal regeneration in some reports, and widely ranging reintervention rates (examples 4.5%–87.5%); specific cardiac patch uses have shown notable failure and reoperation rates, indicating condition-specific concerns for coverage consideration.

These findings relate to cardiovascular uses rather than wound-healing applications but inform evidence caution for the product.

Products with RCT/prospective evidence (DermACELL)

Coverage favored when clinical evidence demonstrates superiority to standard care and trial-like conditions are met:

DermACELL evidence-based coverage: Coverage may be considered when documentation mirrors trial populations and protocols: chronic DFU or VLU meeting study criteria, failure of standard of care, appropriate wound size/duration documentation, and treatment/follow-up consistent with published protocols (typically one application with option for one repeat; weekly assessment up to study endpoints).refer to trial inclusion criteria

DermACELL has RCT and prospective data suggesting benefit versus SOC in selected settings.

Products with insufficient evidence

Not supported / insufficient evidence:

Insufficient evidence products: A range of products (examples: Corplex family, Cryo-Cord, CYGNUS family, Cymetra, Cytal, DermaBind variants, DermaPure, Derma-Gide, Dermacyte, DermaSpan, Dermavest, and others) have few published studies and insufficient evidence to determine benefit; these products are considered unsupported by current evidence for wound indications.

Policy treats these products as not supported absent stronger evidence.

CorMatrix (cardiac) outcomes

Device-specific adverse outcome noted:

CorMatrix cardiac patch concerns: Clinical reports identified high recurrence and reoperation rates (example: 32% recurrence of severe mitral regurgitation and ~28% reoperation related to patch failure) with CorMatrix used for anterior leaflet augmentation, suggesting safety and durability concerns for certain cardiac applications.

Highlights need for caution and further research in cardiovascular uses.

Coverage differentiation by evidence strength

Summary coverage implications based on evidence:

Products lacking adequate evidence: Many named products with few or no published studies (examples across decellularized dermis, amniotic/placental products, and various ECM matrices) have insufficient evidence to determine clinical benefit; coverage should require strong justification or be considered investigational.

Based on multiple product-specific insufficient-evidence statements.

EPICORD trial-aligned coverage: For products with limited RCT evidence (e.g., EPICORD), consider coverage when patient and wound characteristics match trial eligibility (DFU below ankle, persistent ≥30 days, SOC run-in with ≤30% reduction) and SOC was adequately provided.

Derived from EPICORD trial design and inclusion criteria.

dHACA pooled RCT evidence: dHACA (dehydrated human amnion/chorion allograft) pooled RCT evidence demonstrates superiority to SOC for DFU healing at 6 and 12 weeks and faster time to heal; consider coverage for DFUs that meet trial-consistent eligibility and documentation of SOC failure.

Based on systematic review and meta-analysis findings.

dHACM/placental membrane allograft coverage when trial-like criteria met

Covered when ALL of the following study-based criteria are documented:

Primary eligibility (dHACM/placental membrane): Ulcer located on the lower extremity (DFU or VLU) with size ≥1 cm2 and <25 cm2; duration ≥4 weeks; inadequate response to a standardized SOC run-in (e.g., ≤25% closure during run-in); no clinical signs of infection; adequate limb perfusion documented (TcPO2 ≥ 30 mm Hg or ABI 0.7–1.2 or triphasic/biphasic Doppler at the ankle); HbA1c and serum creatinine within trial-specified limits where applicable.Ulcer size ≥1 cm2 and <25 cm2; duration ≥4 weeks; TcPO2 ≥30 mm Hg or ABI 0.7–1.2

These criteria are derived from inclusion criteria used in RCTs of dHACM/placental membranes.

Trial-like exclusions: Exclude ulcers probing to tendon/muscle/capsule/bone, index wound duration >52 weeks without intermittent healing, active malignancy of the ulcer, pregnancy/breastfeeding, recent use of topical growth factors or immunomodulators, or other trial-specified exclusions.

Mirrors exclusion criteria used in the trials referenced.

Treatment and monitoring plan:

Evidence summaries to inform selection and response thresholds

Findings from trials and observational studies summarized below — useful when defining coverage criteria such as patient selection, prior standard care, and expected early response metrics:

VLU dHACM trial findings: In RCTs of dHACM plus multilayer compression vs compression alone, inclusion required full-thickness venous ulcers not down to muscle/tendon/bone, present ≥1 month and treated with compression ≥14 days; primary outcome often included ≥40% closure at 4 weeks with allograft groups showing higher early area reduction and mean wound size reduction (example: 62% vs 32% achieving >40% closure at 4 weeks; mean reduction 48.1% vs 19.0%).4-week 40% area reduction metric

Short-term surrogate outcomes commonly used in trials.

GRAFIX (vCPM/hVWM) evidence summary: vCPM/hVWM studies (RCTs, prospective, retrospective) suggest improved healing in DFUs and refractory VLUs with examples including 59.4% DFU closure in a real-world cohort and 53% healing in a single-center refractory VLU study; noninferiority to Dermagraft was demonstrated in one RCT with subgroup signals for smaller wounds. Evidence is promising but limited by study design heterogeneity and sample sizes.

Use evidence summaries to inform selection and response thresholds when authorizing products.

Amniotic/placental products — DFU coverage

Covered when ALL of the following are met (DFU — trial-aligned criteria):

DFU: prior standard care: Chronic diabetic foot ulcer that has failed an adequate trial of standard wound care, including documented offloading, dressings, and debridement as appropriate.At least 4 weeks of SOC with insufficient response

Trials required SOC run-in periods before randomization.

DFU: perfusion and infection status: Adequate tissue perfusion documented (ABI 0.7–1.2, TcPO2 ≥30 mm Hg, or triphasic/biphasic Doppler) and no active wound infection.ABI 0.7–1.2 or TcPO2 ≥30 mm Hg

Most RCTs excluded poorly perfused or infected wounds.

DFU: wound size and depth: Wound characteristics consistent with supportive trials (document size and depth); smaller-wound subgroups (e.g., ≤5 cm2) may have different expected outcomes; document size for subgroup applicability.

Lyopreserved placental membrane (LPM) — VLU coverage

For venous leg ulcers using lyopreserved placental membrane (LPM):

VLU_LPM_primary: Chronic venous leg ulcer that has failed standard care; wound size consistent with trial subgroup (reported benefit in trials for wounds of approximately 3 to 25 cm2); adequate compression therapy provided prior to and during treatment.wound size 3–25 cm2; 12-week treatment period

Dhillon RCT showed higher closure probability in this size range.

VLU_LPM_treatment_plan: Document plan for weekly application availability and follow-up up to 12 weeks as per trial protocols.12 weeks

Trial assessed outcomes through 12 weeks.

Product-specific coverage conclusions

Coverage conclusions and criteria logic derived from the evidence summaries in this section:

Integra Flowable Wound Matrix: Existing studies have limitations (small size, no blinding, single-center) and evidence is inconclusive; benefit cannot be determined and coverage is not supported absent stronger data.evidence insufficient

See cited trial and ECRI conclusion.

InteguPly / Interfyl / Kerasorb / Keroxx / Lamellas: These products have few or limited studies; current evidence is insufficient to determine a beneficial effect on health outcomes and they are not supported for general coverage without stronger evidence.evidence insufficient

Policy lists product-specific evidence gaps.

Keramatrix: Small controlled and randomized studies show limited positive signals (e.g., faster epithelialization in some subgroups) but overall evidence remains insufficient for definitive coverage conclusions.

Products used during postmastectomy breast reconstruction are addressed under a separate policy. For coverage determinations involving skin or soft-tissue substitutes applied during postmastectomy reconstruction, refer to the Medical Policy titled Breast Reconstruction for the appropriate coverage rules and documentation expectations.

Several individual products are identified in the document as lacking sufficient published clinical evidence. Examples explicitly named include Abiomend Membrane, Abiomend Hydromembrane, Abiomend Xplus variants, and Absolv3 Membrane; the policy states that studies are lacking for these products and therefore a beneficial effect on health outcomes cannot be determined.

The excerpt does not list product-specific categorical exclusions. Instead, it repeatedly characterizes many named products as having few or no published studies and therefore insufficient evidence to determine clinical benefit; absence of supportive evidence may lead to noncoverage or require strong justification when requested.

Clinical trials cited in the review commonly excluded ulcers with active infection and ulcers caused by etiologies other than the trial’s target (for example, venous ulcer trials excluded ulcers not due to venous insufficiency). These trial exclusion criteria indicate that infected wounds and non-target etiologies were not evaluated in the cited evidence base.

The supporting trials generally required adequate tissue perfusion and absence of active infection for enrollment. Use of products in patients with inadequate perfusion or active wound infection was excluded from those study populations and therefore may not be supported by the cited evidence.

The AmnioPlast product series is described primarily for ocular protective use in the document. Because intended indications differ (ocular versus non‑ocular wound types), available product descriptions do not establish evidence for broader non‑ocular wound applications without additional supporting studies.

The document states that requests to use listed products without adequate supporting clinical evidence or documentation may be excluded from coverage. In practice, absence of peer‑reviewed studies or product‑specific data supporting benefit is a basis for denying coverage or requiring substantial clinical justification.

Although the excerpt does not set out many explicit exclusion rules, it emphasizes that use of numerous products for wound treatment is unsupported by sufficient evidence. Where evidence is lacking the document treats such uses as investigational or not medically necessary pending higher‑quality data.

Some products (for example the Corplex family, and variants labeled for packing such as Corplex P/Theracor P/Allacor P) are described in the document as intended for wound packing or as having insufficient clinical data. The excerpt indicates these products are not demonstrated to provide a clinical benefit as primary therapy for wound healing in the evidence reviewed.

The review repeatedly identifies numerous branded products as having few or no published studies; the document states that for these products there is insufficient evidence to determine benefit. Where the policy lists specific product names, it concludes that available data are inadequate to support coverage based on demonstrated health‑outcome improvement.

High‑risk ulcer features and common trial exclusion criteria are summarized in the document. Examples include ulcers that probe to tendon, muscle, capsule, or bone, index wound duration >52 weeks without intermittent healing, and presence of uncontrolled systemic comorbidities or active malignancy of the ulcer; such characteristics typically disqualified patients from the trials cited.

The policy enumerates an extensive list of specific product names considered unproven or not medically necessary for wound healing indications. Examples from the document include, but are not limited to, Abiomend variants, AmnioBand/AmnioBind/AmnioCore/AmnioExcel, Artacent family, AlloSkin, BioVance, Cellesta, CHORIOFIX, Corplex family, DermaPure/DermaSpan, EPIXPRESS, GRAFIX variants, Integra Flowable, Kerecis and many others as listed in the product tables.

Multiple statements in the review emphasize that for many named amniotic/placental and related products the evidence is limited or absent; as a result the policy repeatedly concludes it is not possible to determine a beneficial effect on health outcomes for those products and treats their use as investigational or not medically necessary absent stronger data.

Because the document finds insufficient published comparative evidence for many listed products, it states that use of those products may be considered not medically necessary when requested, particularly if no published evidence demonstrates clinical benefit for the specified indication.

The document explicitly lists a long inventory of products judged as unproven and not medically necessary for the indications reviewed. These enumerated products are therefore treated in the policy as not supported by the current evidence base for wound treatment and similar soft‑tissue indications.

The review lists many named amniotic/placental/dermal products that the authors judged to be unproven for wound indications; examples across the document include AmnioBind/DermaBind, AmnioCore, Amniocyte Plus, AmnioDefend FT Matrix, AMNIOMATRIX/BioDMatrix, AmnioMatrixF3X/F4X, and numerous additional branded items identified in the product lists.

Systematic reviews and technology assessments summarized in the document conclude that current evidence is insufficient to demonstrate that specific skin substitute products are superior to standard of care or to each other across many outcomes; heterogeneity of trial designs and limited long‑term outcome data were cited as major limitations.

The policy states that use of the listed amniotic/placental membrane products may be considered not medically necessary when no published evidence demonstrates a beneficial effect on health outcomes for the requested indication.

Multiple named amniotic/placental membrane products are identified as having insufficient or few published studies; the document therefore concludes that benefit cannot be determined and treats these products as investigational or not medically necessary until stronger evidence is available.

The review identifies numerous products for which only limited or no peer‑reviewed studies exist (for example AmnioBind/DermaBind TL, AmnioCore, Amniocyte Plus, AmnioDefend FT Matrix, AmnioExcel/BioDExcel, AMNIOMATRIX/BioDMatrix, AmnioMatrixF3X/F4X), and therefore considers their effectiveness for wound treatment to be unestablished.

For the many products with limited published evidence, the document states that requests for coverage should be considered not established as medically necessary absent sufficient published studies; in practice this means claims may be denied or require strong clinical justification and product‑specific evidence.

The policy repeatedly states that certain specific products lack adequate clinical evidence to demonstrate a beneficial effect on health outcomes. When no such evidence exists for a listed product, its requested use may be considered not medically necessary or investigational.

The document identifies several products (including items from the Corplex family and other named grafts) as having few published studies; the stated conclusion is that such products are not supported by sufficient evidence for efficacy and therefore are not supported for routine coverage.

Because many products lack supportive comparative evidence, the policy indicates their use may be considered not medically necessary when requested, unless compelling product‑specific data demonstrating benefit are provided to justify coverage.

The document notes that EPIXPRESS has no adequate studies supporting its use for wound treatment; therefore clinical benefit for wound indications is not established in the reviewed evidence.

Across the product reviews the authors repeatedly emphasize that limited study numbers, small sample sizes, and heterogeneous designs prevent determination of a beneficial effect for many products; where evidence is limited the document treats use as investigational and may consider such use not medically necessary.

Several specific products are noted as having limited or inconclusive evidence (for example Integra Flowable Wound Matrix, InteguPly, Interfyl, Keramatrix, Kerasorb, Keroxx, and Lamellas/Lamellas XT); the review describes the evidence for these products as inadequate to determine a clear benefit.

Applicable Billing Codes and Units

Applicable HCPCS Q-codesHCPCS

Q4346	Shelter DM Matrix, per sq cm (add-on, list separately in addition to primary procedure)
Q4337	Artacent Trident, per sq cm (add-on, list separately in addition to primary procedure)
Q4338	Artacent Velos, per sq cm (add-on, list separately in addition to primary procedure)
Q4339	Artacent Vericlen, per sq cm (add-on, list separately in addition to primary procedure)
Q4340	SimpliGraft, per sq cm (add-on, list separately in addition to primary procedure)
Q4341	SimpliMax, per sq cm (add-on, list separately in addition to primary procedure)
Q4342	TheraMend, per sq cm (add-on, list separately in addition to primary procedure)
Q4343	Dermacyte AC Matrix Amniotic Membrane Allograft, per sq cm (add-on, list separately in addition to primary procedure)
Q4344	Tri-Membrane Wrap, per sq cm (add-on, list separately in addition to primary procedure)
Q4345	Matrix HD Allograft Dermis, per sq cm (add-on, list separately in addition to primary procedure)

Prior Authorization, Documentation, and Denial Risk

Prior Authorization

Prior authorization and coding requirements

Prior authorization is required or recommended for many listed skin substitute and membrane products (including Q4*** HCPCS product codes). Requests must use the exact HCPCS/Q-code and billed units that correspond to the specific product (per sq cm, per mg, per cc, etc.). Prior authorization reviews will confirm medical necessity and may require linkage to a primary procedure when the product is billed as an add-on.

Use the exact Q-code and units for authorization requests; do not substitute or estimate units.
Prior authorization required for Q4*** skin substitute codes; include the product-specific code (e.g., Q41xx–Q44xx) on requests and claims.
When billed as an add-on (A2xxx/A4xxx), list separately and link to the primary procedure if applicable.

Prior Authorization

PA recommended for membrane, placental, and limited-evidence products

Prior authorization is recommended for named membrane products and many amniotic/placental, specialized allograft, and scaffold biologic products due to limited or mixed evidence. Reviewers will require clinical justification showing why the advanced product is necessary and why standard care alone is insufficient.

Clinical Evidence and Product Reviews

Burns and wound types: full‑thickness (third‑degree) burns destroy all layers of the skin and may involve subcutaneous tissue, while partial‑thickness (second‑degree) burns involve the epidermis and variable portions of the dermis. The document highlights that some skin substitutes have FDA‑cleared indications for specific burn or surgical uses, whereas many other products lack sufficient clinical evidence for broader wound applications.

Key Definitions and Product Descriptions

inv-154: Full-Thickness Thermal Burn

DefinitionFull-Thickness Thermal Burn (Third-Degree Burn): destruction of all layers of the skin (epidermis and dermis) with variable subcutaneous involvement

Clinical characteristicMay include varying amounts of subcutaneous layer involvement and loss of skin appendages

RelevanceUsed to determine eligibility for dermal substitutes like TransCyte in acute burn coverage

inv-155: Partial-Thickness Thermal Burn

DefinitionPartial-Thickness Thermal Burn (Second-Degree Burn): involves the epidermis and part of the dermis; deep partial-thickness involves most of the dermis

Clinical noteDeep partial-thickness leaves few intact skin appendages and may impair nerve endings

OpenPayer

Skin and Soft Tissue Substitutes (Skin Substitutes Grafts/Cellular and Tissue-Based)

Coverage Criteria for Skin and Soft Tissue Substitutes

Applicable Billing Codes and Units

Prior Authorization, Documentation, and Denial Risk

Clinical Evidence and Product Reviews

Key Definitions and Product Descriptions